IDEMIA
5.10.2020 18:21:12 CEST | Business Wire | Press release
A world first, remote smartphone-based passenger biometric registration gives passengers a smoother and contactless experience from ID registration until they board. Passenger faces - a genuine Open Sesame throughout the airport - are recorded at home on Mona, Lyon Airport’s smartphone app. Having registered in advance, passengers can put their travel documents away as they pass unhindered through the airport.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201005005759/en/
Passenger registration is secured by a biometric match between their smartphone-based face and scans of their ID document and boarding card. This totally accurate and reliable identity management system that IDEMIA has perfected lets passengers speed through all identity control points.
RESA’s latest automatic and biometric compact gate dubbed Major eGate , which caters for disabled people too, comes with an integrated camera so that passengers can pass through to the security restricted area and then board their plane based merely on facial recognition.
IDEMIA’s system is universal, secure and works on all airline systems thanks to RESA’s IATA-certified CUPPS system. This will be available at Lyon Airport for Transavia and TAP flights to Portugal.
While this new service is subject to formal CNIL1 approval, to date CNIL has recommended it to safeguard passenger data and rights.
IDEMIA Executive VP Identity and Public Safety Philippe Barreau said: “As biometric security solutions expert, we are thrilled to deliver a world first alongside our customers Vinci Airports and Lyon Airport and our partner RESA. This trial harnesses contactless biometric technology that gives users an unrivaled airport experience without letting up one jot on security. This bears out our capacity to constantly innovate to safeguard passenger trust and help pave the way for even smoother and more secure future travel .”
RESA CEO Renaud Willard said: “Current covid restrictions forced us to rethink how to take care of passengers and their interactions with airport security staff and equipment. The biometric trial underway at Lyon Airport was made possible by French industrial collaboration, whereby hi-tech saved the day despite the current pandemic and economic crisis. We have shown here that passengers can pass through airport checks fully contactless and without handing over paper documents while shoring up security to boot.”
Vinci Airports France & Americas Area Director Valérie Vesque-Jeancard said: “We are thrilled to launch MONA today, a world first, at a time when airports need game-changing innovations so they can give passengers an even safer, more enjoyable and personalized experience. I warmly congratulate all staff involved including IDEMIA and RESA people, who managed to overcome tough restrictions these last few months and deliver a great trial in barely a year.”
IDEMIA provides both rapid and safe passenger flow solutions to countless airports around the world and manages 30-plus government border control programs. In 2017, IDEMIA installed a facial recognition-based biometric ID control system in Terminal 4 of Singapore’s Changi Airport, from baggage check-in right through to aircraft boarding, including going airside and border crossing. The Company has regularly conducted facial recognition technology trials to make boarding smoother.
RESA’s expertise lies in introducing biometric technology to authenticate airport security staff, who need to connect to airport IT systems. RESA is currently engaged in introducing such technology on top of existing passenger airport systems. Previously, the firm has conducted several pilot tests including in Singapore and Paris airports.
About IDEMIA
IDEMIA, the global leader in Augmented Identity, provides a trusted environment enabling citizens and consumers alike to perform their daily critical activities (such as pay, connect and travel), in the physical as well as digital space.
Securing our identity has become mission critical in the world we live in today. By standing for Augmented Identity, an identity that ensures privacy and trust and guarantees secure, authenticated and verifiable transactions, we reinvent the way we think, produce, use and protect one of our greatest assets – our identity – whether for individuals or for objects, whenever and wherever security matters. We provide Augmented Identity for international clients from Financial, Telecom, Identity, Public Security and IoT sectors.
With close to 15,000 employees around the world, IDEMIA serves clients in 180 countries.
For more information, visit www.idemia.com / Follow @IDEMIAGroup on Twitter
About RESA
Backed by 30 years of experience and 1,000-plus software programs installed in 62 countries, RESA is one of the world’s top airport and airline systems developers.
The firm is an innovative Vendée-based small business that develops, sells and maintains a broad range of integrated software covering all airport system needs, including passenger check-in and boarding, baggage tracing and reconciliation, passenger tracking, automatic gates, self-service kiosks and biometrics, flight management, resource allocation, billing, statistics, business intelligence and messaging.
__________________________________
1
France’s national authority responsible for data privacy
View source version on businesswire.com: https://www.businesswire.com/news/home/20201005005759/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
LTM Launches BlueVerse™ for iRun to Outcreate Managed Services in the Agentic AI Era15.6.2026 08:10:00 CEST | Press release
AI-native operations model enables enterprises to move from reactive service delivery to intelligent, outcome-driven managed services LTM, the Business Creativity partner to the world’s largest enterprises, today announced the launch of BlueVerse™ for iRun, an AI-native managed services model designed to transform traditional IT operations into a resilient, intelligent, and outcome-driven operating model. As enterprise environments grow more complex—spanning hybrid cloud, SaaS, and AI-driven ecosystems—traditional managed services models are increasingly constrained by siloed teams, static processes, and effort-led scaling. BlueVerse for iRun addresses this shift by moving beyond headcount-based delivery to a platform-led approach powered by agentic AI, knowledge convergence, and process-as-code. Built on the BlueVerse ecosystem, iRun creates a unified intelligence layer that brings together enterprise data, telemetry, workflows, and operational context—enabling AI to reason across sys
Azafaros to Present at BIO International Convention 202615.6.2026 07:00:00 CEST | Press release
Azafaros, a private company building a portfolio to become a leader in lysosomal storage disorders (LSDs), focused on addressing neurological symptoms, today announced that it will present at the 2026 BIO International Convention taking place in San Diego, USA, from June 22-25. The company’s presentation is scheduled for Monday, June 22 at 4:30 PM in Theater 4. The presentation will highlight Azafaros’ progress in developing nizubaglustat, its lead investigational compound for the treatment of rare lysosomal storage disorders with neurological involvement, including GM1 and GM2 gangliosidoses (GM1/GM2) and Niemann-Pick type C disease (NPC). Nizubaglustat is currently in two Phase 3 registrational studies (NAVIGATE) treating patients with GM1/GM2 and NPC and expects to report topline data from the studies in 2028. “BIO provides an important opportunity to update our progress as we continue advancing nizubaglustat through late-stage clinical development,” said Stefano Portolano, CEO at A
Teledyne FLIR Defense Launches Black Recon™ Autonomous Micro-Drone15.6.2026 06:05:00 CEST | Press release
Autonomous launch, recovery, and recharge from military vehicles and fixed installations; Three-drone rotation provides persistent surveillance and real-time targeting data in contested environments Teledyne FLIR Defense, part of Teledyne Technologies Incorporated (NYSE: TDY), today announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone system that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260614388428/en/ Teledyne FLIR Defense announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. Black Recon allows crews to launch, operate, recover, and recharge up to three UAS without leaving their platform, reducing operator risk. Designed for vehicle integrati
OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press release
REACH study met its first primary endpoint, showing that Broncho‑Vaxom® (OM‑85) was associated with a 28-38% reduction in respiratory tract infection rates at 12 months and 29-41% reduction at 24 months, comparing post-treatment versus pre-treatment initiation.1 The reduction was observed regardless of the frequency of respiratory tract infections in the previous year (1-3, >3) and across age subgroups (1-5, 6-11, 12-17, 18-64, >64 years).1 By reflecting everyday clinical practice and capturing episodes that necessitated a visit to the doctor, these extensive data offer critical new evidence of the therapy’s long-term relevance for patients suffering from recurrent respiratory tract infections. Evaluating a vast cohort of more than 15,790 paediatric, adolescent, adult and elderly patients in China, Italy, and Belgium, REACH represents the largest and only multi-country real-world evidence study to date for Broncho-Vaxom®.1,2 The study cohort includes patients with different co-morbidit
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 17:15:00 CEST | Press release
In myelofibrosis (MF), INCA033989 delivered rapid and durable clinical benefits including meaningful spleen volume reductions, symptom improvement and anemia responses, both as a monotherapy and in combination with ruxolitinibIn essential thrombocythemia (ET), 87% of patients achieved a hematologic response, including 70% complete responses; responses were rapid (median ~2 weeks to a durable complete hematologic response) and durable (median response duration of 23 weeks)Across MF and ET, INCA033989 consistently reduced mutant CALR (mutCALR) variant allele frequency (VAF) in most evaluable patients, with reductions correlating with clinical responses and supporting its potential for disease modificationFirst-in-class mutCALR-targeted antibody shows potential to modify disease biology in both MF and ETINCA033989 demonstrated a favorable and manageable safety profile with no dose-limiting toxicities, with most patients with MF and ET continuing treatment Incyte (Nasdaq:INCY) today announ
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom